

11 May 2026

BXN secures first supply agreement for medicinal cannabis flower to Costa Rica, expanding LATAM footprint

Key Highlights

- Bioxyne has executed an expanded supply agreement with Remidose LATAM to supply three Dr Watson® cannabis flower stock keeping units (SKUs) to Costa Rica
- Represents the first international supply of medicinal cannabis flower available in Costa Rica's regulated market
- Initial shipment to be made prior to 30 June 2026, with invoice value to exceed \$500,000
- Expansion of the existing December 2025 agreement, highlights early-stage demand and strong partner alignment
- The relationship with Remidose will include the future supply of pastilles to Costa Rica and Panama
- Costa Rica entry establishes a first-mover position and distribution foothold, with opportunities for further growth through Remidose's existing regional network across LATAM

Bioxyne Limited (ASX: BXN) (“Bioxyne” or “the Company”), through its wholly owned subsidiary Breathe Life Sciences (“BLS”), is pleased to announce it has executed an expanded supply agreement with Remidose LATAM SRL (“Remidose”) to include the supply of three Dr Watson® cannabis flower SKUs to Costa Rica. This agreement marks the first international supply of medicinal cannabis flower into Costa Rica's regulated market.

The expansion of the initial December 2025 agreement to include cannabis flower¹, highlights strong early-stage demand and reinforces the strategic alignment between Bioxyne and Remidose.

The expanded agreement builds on the existing relationship between BLS and Remidose, under which BLS will supply cannabis pastilles for distribution into Costa Rica and Panama, further strengthening Bioxyne's presence across LATAM markets.

Product registration for Costa Rica is well advanced and initial shipments of Dr Watson® cannabis flower are expected prior to 30 June 2026, with the first shipment to exceed \$500,000.

¹ BXN ASX Announcement: BXN Secures First-Mover Supply Agreement in Emerging Central American Cannabis Markets, dated 11 December 2025



Based on current demand forecasts, the Company expects repeat orders, subject to market conditions and regulatory approvals.

Bioxyne Chief Executive Officer Sam Watson commented:

“This expansion with Remidose is a great example of how quickly opportunities can evolve once you establish a presence in new markets. We’ve moved from our initial agreement into a broader supply scope in a short period of time, which reflects both the strength of the relationship and the level of demand we’re seeing on the ground.

“LATAM is still early in its development, but that’s exactly where we see the opportunity. Being the first to supply branded medicinal cannabis flower into Costa Rica positions us ahead of competing suppliers and gives us the platform to expand into other LATAM jurisdictions as those markets continue to open.”

Remidose Managing Director Michael Mayne commented:

“We are pleased to be making the first ever shipment of medicinal cannabis flower into Costa Rica and are delighted to be doing this with the Dr Watson®-branded products. Early indications of demand have been exceptionally strong – to the point where initial stock may well be fully committed before product even arrives in market. This is an exciting time for both companies. We see Costa Rica as the foundation for establishing Dr Watson® and Remidose as leaders across the LATAM markets.”

Strategic Rationale and Market Opportunity

Under the agreement, BLS will supply GMP-manufactured cannabis flower products under its Dr Watson® brand, supporting the introduction of the brand into the Costa Rican market.

Costa Rica represents an early-stage regulated medicinal cannabis market with limited competition and significant long-term growth potential, supported by evolving regulatory frameworks and increasing patient access. Bioxyne's entry as the first international supplier of medicinal cannabis flower (soon to be followed by pastilles) into this market establishes early Dr Watson® brand positioning and creates a regulatory and distribution foothold intended to support broader expansion across LATAM.

Bioxyne's established export capability and regulatory experience has enabled the Company to enter the market at an early stage of development, ahead of competing international suppliers currently progressing through approval pathways.

This agreement aligns with Bioxyne's strategy to scale its GMP-certified manufacturing and supply platform across regulated international markets, with Europe and LATAM representing key growth regions.

The expansion also reflects increasing demand for Bioxyne's GMP-manufactured products and supports the continued rollout of the Dr Watson® brand across international markets.

ENDS

Approved by the Board of Bioxyne Limited for release to the ASX.



For further information, please contact:

Bioxyne Limited

Sam Watson
Chief Executive Officer
info@bioxyne.com

NWR Communications

Melissa Tempra
Media & Investor Relations
melissa@nwrcommunications.com.au

Remidose LATAM SRL

Ludwig Muller
General Manager LATAM
Ludwig.muller@remidose.com

About Remidose LATAM SRL

Remidose is a pharmaceutical distributor based in Costa Rica, focused on the import and distribution of medicinal cannabis products across LATAM markets, including Costa Rica and Panama.

About Bioxyne Ltd.

Bioxyne Limited is an Australian pharmaceutical company focused on the development and commercialisation of innovative medicines and active pharmaceutical ingredients. Through its subsidiary, Breathe Life Sciences, Bioxyne is expanding into the production of psychedelic compounds for therapeutic use.



About Breathe Life Sciences (BLS)

Breathe Life Sciences (“BLS”) is a wholly owned subsidiary of Bioxyne Ltd (BXN:ASX) and GMP-licensed manufacturer, wholesaler, importer and exporter of controlled substances (S3, S4, S8, S9), including medicinal cannabis, Psilocybin, and MDMA.

BLS was founded in 2018 and has quickly expanded into a multi-national business focused on alternative therapeutics and investigational medicines. The company’s corporate head office is in Sydney, with operations and licensed manufacturing, warehousing, import/export, sales and distribution centres in Queensland (Australia), Nagoya (Japan), Scotland (UK), and Prague (Czechia).

The BLS business model is focused on manufacturing final dose form medicines, sales and distribution. BLS sources raw materials and API from suppliers in 5 continents and is the Australian market leading manufacturer of therapeutic goods including cannabis, MDMA, and Psilocybin.

Outside of Australia the BLS Group operates in pharmaceuticals, medical cannabis, consumer health products, and novel foods (CBD). In the UK, Europe and Japan, the Company engages in the following activities:

- a) Owner of the Dr Watson® brand in the UK, Japan, Australia and New Zealand. Internationally recognised for its cannabis-based food supplements, lifestyle products, functional mushrooms and nootropics, and prescription-only medicines.
- b) Contract medicine manufacture and white label manufacture of medicinal products for human use.
- c) Wholesale distribution, import and export of controlled drugs, finished medicinal products, and active pharmaceutical ingredients.
- d) Research and development of novel medicines.
- e) Direct sales via online and wholesale of BLS-owned consumer brands, such as Dr Watson®

United Kingdom: [drwatsoncbd.com](https://www.drwatsoncbd.com)

UK / EU: [breathelifesciences.com](https://www.breathelifesciences.com)

- f) Export and supply of medicinal cannabis products and manufacturing services to UK and European markets.

Corporate: [bioxyne.com](https://www.bioxyne.com)

Australia: [bls.com.au](https://www.bls.com.au)

International: [breathelifesciences.com](https://www.breathelifesciences.com)